Basic Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2019; 25(22): 2752-2762
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2752
MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells
Shun-Zhen Zheng, Ping Sun, Jian-Ping Wang, Yong Liu, Wei Gong, Jun Liu
Shun-Zhen Zheng, Jian-Ping Wang, Yong Liu, Wei Gong, Jun Liu, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China
Ping Sun, Department of Clinical Laboratory, Blood Station of Jinan, Jinan 250021, Shandong Province, China
Author contributions: Zheng SZ and Li J designed the research; Zheng SZ, Sun P, Wang JP, Liu Y, and Gong W performed the research; Sun P and Wang JP analyzed the data; Zheng SZ wrote the paper.
Supported by: the National Natural Science Foundation of China, No. 81302124, Shandong Key R and D Program No. 2017GSF218038 and Shandong Provincial Natural Science Foundation, No. ZR2014HP065.
Institutional review board statement: This study was reviewed and approved by the Medical Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University.
Institutional animal care and use committee statement: No animal models were used in this study.
Conflict-of-interest statement: None of the authors has any conflicts of interest to declare.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: No animal models were used in this study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jun Liu, MD, Professor, Surgeon, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun1967@126.com
Telephone: +86-531-68776932 Fax: +86-531-87925615
Received: March 14, 2019
Peer-review started: March 14, 2019
First decision: April 4, 2019
Revised: April 13, 2019
Accepted: April 29, 2019
Article in press: April 29, 2019
Published online: June 14, 2019
Processing time: 95 Days and 3.2 Hours
Core Tip

Core tip: Hepatocellular carcinoma (HCC) is the third leading cause of death from malignant tumors worldwide. The prognosis remains poor, and the overall efficacy is still unsatisfactory. Chemotherapy resistance is the most significant cause of poor HCC outcome. We found that upregulation of miR-34a can increase the chemosensitivity of HCC cells to doxorubicin. MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating multidrug resistance protein 1/P glycoprotein and AXL, which may be related to p53 expression.